Clinical Trials Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$19,960	4
2024	Research	$8,130	10
2023	Research	$851	3
2022	Research	$59,482	27
2021	Research	$83,295	13
2020	Research	$103,995	11
2019	Research	$79,634	8

Breakdown

Who paid Research payments · program years 2019–2025

Amneal Pharmaceuticals LLC $120,056 15 payments
SK Life Science, Inc. $103,386 32 payments
Eisai Inc. $52,023 5 payments
Genentech, Inc. $29,554 3 payments
AbbVie, Inc. $28,091 14 payments
Ucb SA $11,562 5 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $9,000 1 payment
UCB Biosciences Inc. $1,677 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations $80,668 7 payments
Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures $52,023 5 payments
Ykp3089c013 $46,659 23 payments
An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations $39,387 8 payments
059566 $38,605 4 payments
Prodromal to Mild Ad $29,554 3 payments
1-Q3ras $14,492 3 payments
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures $14,369 2 payments
A phase 1b, Single-blind, Placebo-controlled, Adaptive design, Outpatient Trial to Assess the effects of Single Oral Tablet Doses of OPC-214870 on Photic-Induced Paroxysmal Electroencephalogram Responses in Subjects Who Have Demonstrated Photoeplipeptiform Discharges on Electroencephalogram with or without seizures. $9,000 1 payment
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures $6,685 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.